BiotechTube

SHR4640 + placebo

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gout; Hyperuricemia

Conditions

Gout; Hyperuricemia

Trial Timeline

Jul 1, 2016 โ†’ Mar 1, 2017

NCT ID
NCT02890966

About SHR4640 + placebo

SHR4640 + placebo is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Gout; Hyperuricemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02890966. Target conditions include Gout; Hyperuricemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT02890966Phase 1Completed
NCT02815839Phase 1Completed

Competing Products

20 competing products in Gout; Hyperuricemia

See all competitors
ProductCompanyStageHype Score
febuxostat + AllopurinolAstellas PharmaPhase 3
77
Dotinurad + FebuxostatEisaiPhase 3
77
BaricitinibEli LillyPhase 2
52
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 1
33
SHR4640 tablet + SHR4640 tablet + febuxostat tablet + SHR4640 placebo tabletJiangsu Hengrui MedicinePhase 2
52
repaglinide; midazolam; SHR4640 + repaglinide; midazolam; SHR4640; SHR4640 placebo + repaglinide; midazolam; SHR4640 placeboJiangsu Hengrui MedicinePhase 1
33
SHR4640 dose1 + SHR4640 dose2 + Placebo oral tablet + Allopurinol 300 MGJiangsu Hengrui MedicinePhase 3
77
Colchicine + Febuxostat + SHR4640Jiangsu Hengrui MedicinePhase 1
33
SHR4640 + AllopurinolJiangsu Hengrui MedicinePhase 3
77
SHR4640 ๏ผ›Febuxostat + SHR4640 ; Febuxostat + SHR4640 + SHR4640 + FebuxostatJiangsu Hengrui MedicinePhase 2
52
SHR4640Jiangsu Hengrui MedicinePhase 1
33
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
77
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
77
SHR4640 + PlaceboJiangsu Hengrui MedicinePhase 1
33
Zurampicยฎ + Control group: xanthine oxidase inhibitor monotherapyAstraZenecaPre-clinical
23
Risk of selected safety eventsAstraZenecaPre-clinical
23
AZD6140 + Placebo to match AZD6140AstraZenecaPhase 1
33
RDEA3170 + Allopurinol + PlaceboAstraZenecaPhase 2
52
RDEA3170 + Febuxostat + BenzbromaroneAstraZenecaPhase 1/2
41
Canakinumab pre-filled syringe + Canakinumab lyophilized powder + Triamcinolone Acetonide + PlaceboNovartisPhase 3
77

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85